## International Application PCT/EP00/05854 Attorney Docket No.: BM-594

- 31. A process for expressing the polynucleotide of Claim 30 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.
- 32. The isolated polypeptide of claim 27, wherein the polypeptide is according to (b).



- 33. An isolated polynucleotide encoding a polypeptide of Claim 32 or the full complement to the isolated polynucleotide.
- 34. The isolated polypeptide of claim 27, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
- 35. The isolated polypeptide of claim 27, wherein the isolated polypeptide consists of SEQ ID NO:2 or SEQ ID NO:4.
- 36. An isolated polynucleotide encoding the polypeptide of Claim 35 or the full complement to the isolated polynucleotide.
- 37. A process for expressing the polynucleotide of Claim 36 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.
- 38. A fusion protein comprising the isolated polypeptide of Claim 21.
- 39. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
- 40. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of SEQ ID NO:1 or SEQ ID NO:3 minus the complement of any stop codon, wherein the hybridization conditions include incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and

International Application PCT/EP00/05854
Attorney Docket No.: BM45394

20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at  $65^{\circ}$ C; and, wherein the polynucleotide sequence is identical to SEQ ID NO:1 or SEQ ID NO:3 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NO:1 or SEQ ID NO:3 minus any terminal stop codon,  $\mathbf{n}_n$  nucleotides are substituted, inserted or deleted, wherein  $\mathbf{n}_n$  satisfies the following expression

$$n_n \leq x_n - (x_n \bullet y)$$

wherein  $\mathbf{x}_n$  is the total number of nucleotides in SEQ ID NO:1 or SEQ ID NO:3 minus any terminal stop codon  $\mathbf{y}$  is at least 0.95, and wherein any non-integer product of  $\mathbf{x}_n$  and  $\mathbf{y}$  is rounded down to the nearest integer before subtracting the product from  $\mathbf{x}_n$ ; and wherein the polynucleotide sequence detects *Moraxella catarrhalis*.

- 41. An expression vector comprising the isolated polynucleotide of Claim 28.
- 42. A host cell transformed with the expression vector of Claim 41.
- 43. A vaccine comprising the polypeptide of Claim 27 and a pharmaceutically acceptable carrier.
- 44. The vaccine of Claim 43, wherein the vaccine comprises at least one other *Moraxella* catarrhalis antigen.
- 45. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 27.
- 46. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 27.
- 47. A method of diagnosing a *Moraxella catarrhalis* infection comprising identifying a polypeptide of Claim 27, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.
- 48. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 28.

